Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.68 USD | +2.49% | -2.43% | +2.56% |
Financials (USD)
Sales 2024 * | 604M | Sales 2025 * | 627M | Capitalization | 1.59B |
---|---|---|---|---|---|
Net income 2024 * | 14M | Net income 2025 * | -41M | EV / Sales 2024 * | 2.64 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.54 x |
P/E ratio 2024 * |
116
x | P/E ratio 2025 * |
-39.1
x | Employees | 652 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.98% |
Latest transcript on Supernus Pharmaceuticals, Inc.
1 day | +2.49% | ||
1 week | -2.43% | ||
Current month | -1.40% | ||
1 month | -1.85% | ||
3 months | +9.48% | ||
6 months | +8.60% | ||
Current year | +2.56% |
Managers | Title | Age | Since |
---|---|---|---|
Jack Khattar
FOU | Founder | 62 | 05-03-29 |
Timothy Dec
DFI | Director of Finance/CFO | 66 | 21-08-22 |
Frank Mottola
CTO | Chief Tech/Sci/R&D Officer | 52 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Georges Gemayel
BRD | Director/Board Member | 64 | 15-03-22 |
Charles Newhall
CHM | Chairman | 79 | 05-03-29 |
John Siebert
BRD | Director/Board Member | 84 | 10-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.94% | 28 M€ | -1.45% | ||
0.94% | 14 M€ | -4.28% | ||
0.38% | 25 M€ | -2.33% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 29.68 | +2.49% | 549,388 |
24-05-10 | 28.96 | -3.47% | 922,410 |
24-05-09 | 30 | -4.15% | 1,066,039 |
24-05-08 | 31.3 | +0.48% | 461,434 |
24-05-07 | 31.15 | +2.40% | 471,705 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.56% | 1.59B | |
+7.22% | 72.81B | |
+12.72% | 9.13B | |
-11.75% | 5.13B | |
+59.61% | 4.99B | |
+2.62% | 3.9B | |
-17.54% | 2.48B | |
+21.35% | 2.42B | |
-27.82% | 2.32B | |
+25.13% | 2.17B |
- Stock Market
- Equities
- SUPN Stock